Was the CRSP CMO share sale a discretionary trade or tax-related?

The sale is described as tax-related and non-discretionary. Footnotes state 3,786 shares were sold solely to cover tax withholding from RSU vesting, mandated by CRISPR Therapeutics’ RSU Settlement Policy rather than an elective open-market decision.

CRISPR Therapeutics (CRSP) CMO nets shares after mandated RSU tax sale

Q: How many CRSP shares did the CMO sell in the latest Form 4?

The CMO sold 3,786 CRISPR Therapeutics Common Shares. These shares were sold at $55.62 per share specifically to cover tax withholding tied to RSU vesting, and the sale is described as non-discretionary under the company’s RSU Settlement Policy.

Q: What RSU award schedule is disclosed for CRISPR Therapeutics (CRSP) CMO?

The CMO’s RSU award covers 40,000 Common Shares. One-quarter vests on May 28 of each year from 2025 through 2028, creating four 10,000-share tranches with annual vesting over this multi-year period, subject to the award’s standard terms.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

CRISPR Therapeutics AG Chief Medical Officer Naimish Patel reported RSU vesting and a related share sale. On May 28, 10,000 Restricted Stock Units converted into 10,000 Common Shares at $0.00 per share. On May 29, 3,786 Common Shares were sold at $55.62 per share to cover tax withholding, as mandated by the company’s RSU Settlement Policy and described as non-discretionary. Following these transactions, Patel directly held 19,357 Common Shares. The underlying RSU award covers 40,000 shares, with 10,000-share tranches scheduled to vest annually from 2025 through 2028.

Insider Trade Summary

Net Seller: 3,786 shares ($210,577)

Net Sell 3 txns

Insider Patel Naimish

Role Chief Medical Officer

Sold 3,786 shs ($211K)

Type	Security	Shares	Price	Value
Sale	Common Shares	3,786	$55.62	$211K
Exercise	Restricted Stock Units	10,000	$0.00	--
Exercise	Common Shares	10,000	$0.00	--

Holdings After Transaction: Common Shares — 19,357 shares (Direct, null); Restricted Stock Units — 20,000 shares (Direct, null)

Footnotes (1)

Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. This restricted stock unit award was granted on May 28, 2024 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on May 28, 2025, (ii) one quarter of the shares vesting on May 28, 2026, (iii) one quarter of the shares vesting on May 28, 2027, and (iv) one quarter of the shares vesting on May 28, 2028.

Key Figures

Shares sold for taxes: 3,786 shares Sale price per share: $55.62 per share RSUs converted: 10,000 RSUs +3 more

6 metrics

Shares sold for taxes 3,786 shares Common Shares sold at $55.62 on May 29, 2026 to cover tax withholding

Sale price per share $55.62 per share Price for 3,786 Common Shares sold on May 29, 2026

RSUs converted 10,000 RSUs Restricted Stock Units converted into Common Shares on May 28, 2026

Shares held after transactions 19,357 shares Direct Common Share holdings following May 2026 transactions

RSU award size 40,000 RSUs Restricted Stock Unit award granted May 28, 2024 over four annual tranches

Remaining RSUs after conversion 20,000 RSUs Derivative RSU balance reported following 10,000-unit conversion

Key Terms

Restricted Stock Units, RSU Settlement Policy, derivative exercise/conversion, open-market sale

4 terms

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSU Settlement Policy financial

"This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation"

derivative exercise/conversion financial

"transaction_action": "derivative exercise/conversion""

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/01/2026 - 05:35 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Naimish

(Last)

(First)

(Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON

MASSACHUSETTS

02127

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Shares	05/28/2026		M		10,000	A	⁽¹⁾	23,143	D
Common Shares	05/29/2026		S		3,786⁽²⁾	D	$55.62	19,357	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	05/28/2026		M			10,000	⁽³⁾	⁽³⁾	Common Shares	10,000	⁽¹⁾	20,000	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

2. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

3. This restricted stock unit award was granted on May 28, 2024 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on May 28, 2025, (ii) one quarter of the shares vesting on May 28, 2026, (iii) one quarter of the shares vesting on May 28, 2027, and (iv) one quarter of the shares vesting on May 28, 2028.

	Elizabeth Ryland Waldinger, attorney-in-fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did CRISPR Therapeutics (CRSP) CMO report?

CRISPR Therapeutics CMO Naimish Patel reported RSU vesting and a tax-related sale. 10,000 Restricted Stock Units converted into Common Shares, and 3,786 shares were sold to satisfy tax withholding obligations mandated by the company’s RSU Settlement Policy.

How many CRSP shares did the CMO sell in the latest Form 4?

The CMO sold 3,786 CRISPR Therapeutics Common Shares. These shares were sold at $55.62 per share specifically to cover tax withholding tied to RSU vesting, and the sale is described as non-discretionary under the company’s RSU Settlement Policy.

How many CRISPR Therapeutics (CRSP) shares does the CMO hold after these transactions?

After the transactions, the CMO directly holds 19,357 Common Shares. This figure reflects the net position following the 10,000-share RSU conversion and the sale of 3,786 shares to cover tax obligations connected with that vesting event.

What RSU award schedule is disclosed for CRISPR Therapeutics (CRSP) CMO?

The CMO’s RSU award covers 40,000 Common Shares. One-quarter vests on May 28 of each year from 2025 through 2028, creating four 10,000-share tranches with annual vesting over this multi-year period, subject to the award’s standard terms.

What type of securities did the CRSP CMO transact in this Form 4?

The CMO transacted in Common Shares and Restricted Stock Units. 10,000 RSUs were converted into Common Shares, then 3,786 of those shares were sold to satisfy tax withholding requirements associated with the vesting event.